Kiora Pharmaceuticals Presents Plans for Global Phase 3 Trial of KIO-401 in Retinal Artery Occlusion
Bitget2026/10/29 11:25- Kiora Pharmaceuticals added KIO-401, a Phase 3-ready oral calpain inhibitor for central retinal artery occlusion, securing rights outside Asia from Senju Pharmaceutical.
- A planned global Phase 3 trial will enroll approximately 144 patients across up to 50 sites.
- Japan Phase 3 visual acuity results showed p=0.0949 overall versus p=0.0195 in patients with baseline vision worse than 20/400.
- Planned NAION development includes a Phase 2b trial enrolling approximately 272 patients, with label expansion targeted for 2033.
- KIO-301 remains in an actively enrolling Phase 2 trial for advanced retinitis pigmentosa.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Marvell Technology (MRVL.US) $115 billion "merger of the century" faces lukewarm reception! Stock has dropped over 40%, experts estimate only a 50% chance of completion
Marvell plans to acquire Lamington for 115 billions USD to strengthen its position in AI, but the probability of completion is only 50%. The two stocks have dropped by nearly 40% and about 35% respectively, with Chinese regulatory approval being the biggest uncertainty.
Amid opposition to data centers, Musk doubles down: SpaceX (SPCX.US) plans to build a $24 billion computing center and gas power plant in Texas.
According to a public hearing notice published on the Starbase website, SpaceX plans to build, own, and operate a gas-fired power plant and a supercomputing facility at its company town in Starbase, Texas.
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
Crypto prices
More
